Major Flaw In Valeant Pharmaceuticals Ad Hoc Committee’s Statements by TheSkeptic21k, Bored with the noise
Late on February 22nd, 2015 after four months of work, Valeant Pharmaceuticals released a statement about their Ad Hoc Committee’s review of Philidor and related accounting. As of today, Valeant has yet to file an 8-K with respect to that statement, but they may be distracted by other priorities, such as their recently disclosed SEC subpoena.
There is a major problem with the statement they put out on February 22nd and reiterated in their NT 10-K filed yesterday. Before we get to the major problem with the statement, lets explore some other background issues from a year ago.
- On February 20th, 2015 Valeant...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full ArticleAlready a member? Log in here
